Sierra Oncology Inc (SRRA) Forecast, Price Target & Analyst Ratings

NASDAQ:SRRA • US82640U4040

Current stock price

54.99
+0.02 (+0.04%)
At close:
54.99
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Sierra Oncology Inc (SRRA).

Forecast Snapshot

Consensus Price Target

Price Target
$56.10
+ 2.02% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Aug 4, 2022
Period
Q2 / 2022
EPS Estimate
-$0.97
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
76.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$56.10
Upside
+ 2.02%
From current price of $54.99 to mean target of $56.10, Based on 10 analyst forecasts
Low
$55.55
Median
$56.10
High
$57.75

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

10 Wall Street analysts provided a forecast for the next 12 months for SRRA. The average price target is 56.1 null. This implies a price increase of 2.02% is expected in the next year compared to the current price of 54.99.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

SRRA Current Analyst RatingSRRA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

SRRA Historical Analyst RatingsSRRA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
76.00%
SRRA was analyzed by 10 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about SRRA.
In the previous month the buy percentage consensus was at a similar level.
SRRA was analyzed by 10 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2022-04-14OppenheimerDowngrade Outperform -> Perform
2022-04-14JefferiesDowngrade Buy -> Hold
2022-04-13HC Wainwright & Co.Downgrade Buy -> Neutral
2022-01-31HC Wainwright & Co.Maintains Buy
2021-11-30Cantor FitzgeraldMaintains Overweight
2021-11-05HC Wainwright & Co.Maintains Buy
2021-09-27Cantor FitzgeraldInitiate Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
Aug 4, 2022
Period
Q2 / 2022
EPS Estimate
-$0.97
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
41.98%
Number of Analysts
4

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

SRRA is expected to report earnings on 8/4/2022. The consensus EPS estimate for the next earnings is -0.97 null and the consensus revenue estimate is 0 null.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2018 2019 2020 2021 2022 2023 2024 2025 2026
Revenue
YoY % growth
SRRA revenue by date.SRRA revenue by date.
300K
-100.00%		29.269M173.586M
493.07%		425.456M
145.10%		1.064B
150.00%
EBITDA
YoY % growth
SRRA ebitda by date.SRRA ebitda by date.
-55.31M
-30.57%		-66.91M
-20.97%		-64.7M
3.30%		N/A
-45.72%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
SRRA ebit by date.SRRA ebit by date.
-55.42M
-30.03%		-66.99M
-20.88%		-64.94M
3.06%		-93.539M
-45.64%		-100.978M
-6.76%		-89.993M
10.88%		2.825M
103.14%		1.278M
-54.77%		589.465K
-53.87%
Operating Margin
SRRA operating margin by date.SRRA operating margin by date.
N/AN/A-21,646.67%N/AN/A-307.47%1.63%0.30%0.06%
EPS
YoY % growth
SRRA eps by date.SRRA eps by date.
-30.00
11.76%		-29.48
1.73%		-5.91
79.95%		-7.22
-20.98%		-4.89
31.62%		-3.94
19.37%		0.02
100.60%		0.01
-60.18%		0.00
-59.38%

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q2 / 22 Q3 / 22 Q4 / 22
EPS
Q2Q % growth		-0.97
41.98%		-1.12
46.81%		-1.30
22.13%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/AN/A
EBIT
Q2Q % growth		-21.447M
-4.26%		-25.045M
12.43%		-28.494M
-11.35%

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

SRRA Yearly Revenue VS EstimatesSRRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 200M 400M 600M 800M 1B
SRRA Yearly EPS VS EstimatesSRRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -100 -200 -300 -400

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
26.06%
EPS Next 5 Year
14.88%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

Sierra Oncology Inc / SRRA Forecast FAQ

Can you provide the average price target for Sierra Oncology Inc stock?

10 analysts have analysed SRRA and the average price target is 56.1 null. This implies a price increase of 2.02% is expected in the next year compared to the current price of 54.99.

What is the next earnings date for SRRA stock?

Sierra Oncology Inc (SRRA) will report earnings on 2022-08-04, after the market close.

What are the consensus estimates for Sierra Oncology Inc (SRRA) next earnings?

The consensus EPS estimate for the next earnings of Sierra Oncology Inc (SRRA) is -0.97 null and the consensus revenue estimate is 0 null.